Targeting of meta-iodobenzylguanidine to SK-N-SH human neuroblastoma xenografts: Tissue distribution, metabolism and therapeutic efficacy

International Journal of Cancer

Volumn 87, Issue 3, 2000, Pages 412-422

  Rutgers, Marja ^a   Buitenhuis, Corine K M ^a   Hoefnagel, Cees A ^a   Voute P A ^b   Smets, Lou A ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131;

ADOLESCENT; ANIMAL MODEL; ARTICLE; CANCER RADIOTHERAPY; CONTROLLED STUDY; DOSIMETRY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; MALE; MOUSE; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; STRAIN DIFFERENCE; TISSUE DISTRIBUTION; TUMOR XENOGRAFT;

3-IODOBENZYLGUANIDINE; ANIMALS; BIOTRANSFORMATION; DOSE FRACTIONATION; DRUG ADMINISTRATION SCHEDULE; HUMANS; IODINE RADIOISOTOPES; MICE; MICE, INBRED C3H; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEUROBLASTOMA; RADIOISOTOPE TELETHERAPY; RADIOMETRY; RADIOPHARMACEUTICALS; SPECIES SPECIFICITY; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0034255674     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0215(20000801)87:3<412::AID-IJC16>3.0.CO;2-X     Document Type: Article

References (43)

1. BEGG, A.C., DEURLOO, M.J.M., KOP, W. and BARTELINK, H., Improvement of combined modality therapy with cisplatin and radiation using intratumoral drug administration in murine tumors. Radiother. Oncol., 31, 129-137 (1994).
2. BIEDLER, J.L., HELSON, L. and SPENGLER, B.A., Morphology and growth, tumorigenicity, and cytogenetics of human neuroblastoma cells in continuous culture. Cancer Res., 33, 2643-2652 (1973).
3. 131I-labeled monoclonal antibody CC49. Cancer Res. (Suppl.), 55, 5881s-5887s (1995).
4. BUCHSBAUM, D.J., LANGMUIR, V.K. and WESSELS, B.W., Experimental radioimmunotherapy. Med. Phys., 20, 551-567 (1993).
5. D2-specific monoclonal antibody against human neuroblastoma xenografted in nude mice. J. nat. Cancer Inst., 77, 739-745 (1986).
6. CLERC, J., HALPERN, S., FOURRÉ, F., BRIANÇON, C., JEUSSET, J. and FRAGU, P., SIMS microscopy imaging of the intratumor biodistribution of metaiodobenzylguanidine in the human SK-N-SH neuroblastoma cell line xenografted into nude mice. J. Nucl. Med., 34, 1565-1570 (1993).
7. DE KRAKER, J., HOEFNAGEL, C.A., CARON, H., VALDÉS OLMOS, R.A., ZSIROS, J., HEIJ, H.A. and VOÛTE, P.A., First line targeted radiotherapy, a new concept in the treatment of advanced stage neuroblastoma. Eur. J. Cancer. 31A, 600-602 (1995).
8. FIELDING, S.L., FLOWER, M.A., ACKERY, D., KEMSHEAD, J.T., LASHFORD, L.S. and LEWIS, I., Dosimetry of iodine-131 metaiodobenzylguanidine for treatment of resistant neuroblastoma: result of a UK study. Eur. J. Nucl. Med., 18, 308-316 (1991).
9. FOWLER, J.F., Radiobiological aspects of low dose rates in radioimmunotherapy. Int. J. Radiat. Oncol. Biol. Phys., 18, 1261-1269 (1990).
10. FREUDENTHAL, R.I., LEBER, A.P., EMMERLING, D.C., KERCHNER, G.A. and OVEJERA, A.A., Comparison of the drug metabolizing enzymes in the liver and kidneys from homozygous nude Swiss, heterozygous normal Swiss, homozygous normal Swiss and DBA/2 mice. Res. Commun. Chem. Pathol. Pharmacol., 15, 267-278 (1976).
11. 131I-meta-iodobenzylguanidine in two neuroblastoma xenografts. Brit. J. Radiol., 67, 573-578 (1994).
12. HOEFNAGEL, C.A. and DE KRAKER, J., Childhood neoplasia. In: I.P.C. Murray and P.J. Ell (eds.), Nuclear medicine in clinical diagnosis and treatment (2nd ed.), pp. 1001-1014. Churchill Livingstone. London (1998).
13. HOEFNAGEL, C.A. and LEWINGTON, V.J., MIBG therapy. In: I.P.C. Murray and P.J. Ell (eds.), Nuclear medicine in clinical diagnosis and treatment (2nd ed.), pp. 1067-1081, Churchill Livingstone, London (1998).
14. HUMM, J.L., Problems and advances in the dosimetry of radionuclide targeted therapy. In: M.-L. Sautter-Bihl, H. Bihl, and M. Wannenmacher (eds.), Recent results in cancer research, Vol. 14, pp. 37-65, Springer-Verlag, Berlin (1996).
15. KAIREMO, K.J.A., Radioimmunotherapy of solid cancers. A review. Acta Oncol., 35, 343-355 (1996).
16. KNOX, S.J., GORIS, M.L. and WESSELS, B.W., Overview of animal studies comparing radioimmunotherapy with dose equivalent external beam irradiation. Radiother. Oncol., 23, 111-117 (1992).
17. LANGMUIR, V.K., FOWLER, J.F., KNOX, S.J., WESSELS, B.W., SUTHERLAND, R.M. and WONG, J.Y.C., Radiobiology of radiolabeled antibody therapy as applied to tumor dosimetry. Med. Phys., 20, 601-610 (1993).
18. 131I-radiolabeled murine monoclonal antibody in a human glioma xenograft model. Cancer Res., 48, 559-566 (1988).
19. LEICHNER, P.K. and KWOK, C.S., Tumor dosimetry in radioimmunotherapy: methods of calculations for beta particles. Med. Phys., 20, 529-534 (1993).
20. LOESBERG, C., VAN ROOIJ, H. and SMETS, L.A., Meta-iodobenzylguanidine (MIBG), a novel high-affinity substrate for cholera toxin that interferes with cellular mono(ADP-ribosylation). Biochim. Biophys. Acta, 1037, 92-99 (1990).
21. LOEVINGER, R., BUDINGER, T.F. and WATSON, E., MIRD primer for absorbed dose calculations (rev. ed.), Society of Nuclear Medicine, New York (1991).
22. MARCHESE, M.J., ZAIDER, M. and HALL, E.J., Dose-rate effects in normal and malignant cells of human origin. Brit. J. Radiol., 60, 573-576 (1987).
23. 131I-metaiodobenzylguanidine with autologous hone marrow support in refractory neuroblastoma. J. clin. Oncol., 16, 229-236 (1998).
24. 131I]metaiodobenzylguanidine therapy for patients with refractory neuroblastoma. J. nucl. Biol. Med., 35, 244-247 (1991).
25. MEREDITH, R.F., JOHNSON, T.K., PLOTT, G., MACEY, D.J., VESSELLA, R.L., WILSON, L.A., BREITZ, H.B. and WILLIAMS, L.E., Dosimetry of solid tumors. Med Phys., 20, 583-592 (1993).
26. 131]iodobenzylguanidine (I-131 MIBG) in man: evaluation by scintigraphy. J. nucl. Med., 24, 672-682 (1983).
27. O'DONOGHUE, J., The impact of tumor cell proliferation in radioimmunotherapy. Cancer, 73, 974-980 (1994).
28. 131iodine-labeled antibody for a colon cancer model. Cancer Res. (Suppl.), 55, 5811s-5816s (1995).
29. 131I]MIBG in xenografted BALB/c nu/nu mice. In: A.E. Evans, J.L. Biedler, G.M. Brodeur, G.J. D'Angio, and A. Nakagawara (eds.), Advances in neuroblastoma research 4, pp. 466-467, Wiley-Liss, New York (1994).
30. 131I-MIBG (MIBG) [abstract]. Eur. J. nucl. Med., 25, 934 (1998).
31. 131I]-metaiodobenzylguanidine (MIBG) biodistribution and targeted radiotherapy. In: A.E. Evans, G.J. D'Angio, A.G. Knudson, and R.C. Seeger (eds.), Advances in neuroblastoma research 3, pp. 471-478, Wiley-Liss, New York (1991).
32. RUTGERS, M., TYTGAT, G.A.M., VERWIJS-JANSSEN, M., BUITENHUIS, C., VOÛTE, P.A. and SMETS, L.A., Uptake of the neuron-blocking agent metaiodobenzylguanidine and serotonin by human platelets and neuro-adrenergic tumour cells. Int. J. Cancer, 54, 290-295 (1993).
33. SAUTTER-BIHL, M.L., WESSELY, R. and BIHL, H., Comparison of systemic radiotherapy with I-131-labeled monoclonal antibody BW575/9 to external beam radiotherapy in human neuroblastoma xenografts. Strahlenther. Onkol., 169, 595-600 (1993).
34. 131I-mIBG in nude mice hosting human neuroblastoma xenografts. Strahlenther. Onkol., 165, 566-568 (1989).
35. SHULKIN, B.L. and SHAPIRO, B., Current concepts on the diagnostic use of MIBG in children. J. nucl. Med., 39, 679-688 (1998).
36. SMETS, L., JANSSEN, M., RUTGERS, M., RITZEN, K. and BUITENHUIS, C., Pharmacokinetics and intracellular distribution of the tumor-targeted radiopharmaceutical m-iodo-benzylguanidine in SK-N-SH neuroblastoma and PC-12 pheochromocytoma cells. Int. J. Cancer, 48, 609-615 (1991).
37. UGUR, O., KOSTAKOGLU, L., HUI, E.T., FISHER, D.R., GARMESTANI, K., GANSOW, O.A., CHEUNG, N.-K.V. and LARSON, S.M., Comparison of the targeting characteristics of various radioimmunoconjugates for radioimmunotherapy of neuroblastoma: dosimetry calculations incorporating cross-organ beta doses. Nucl. Med. Biol., 23, 1-8 (1996).
38. 131I]MIBG in nude mice bearing SK-N-SH human neuroblastoma xenografts: effects of specific activity. Brit. J. Cancer, 73, 1171-1177 (1996a).
39. 211At]astatobenzylguanidine in an athymic mouse human neuroblastoma xenograft model. Nucl. Med. Biol., 23, 851-856 (1996b).
40. VOÛTE, P.A., VAN DER KLEIJ, A.J., DE KRAKER, J., HOEFNAGEL, C.A., TIEL-VAN BUUL, M.M.C. and VAN GENNIP, H., Clinical experience with radiation enhancement by hyperbaric oxygen in children with recurrent neuroblastoma stage IV. Eur. J. Cancer, 31A, 596-600 (1995).
41. VRIESENDORP, H.M., QUADRI, S.M., ANDERSSON, B.S. and DICKE, K.A., Hematologic side effects of radiolabeled immunoglobulin therapy. Exp. Hematol., 24, 1183-1190 (1996).
42. WAFELMAN, A.R., HOEFNAGEL, CA., MAES, R.A.A. and BEIJNEN, J.H., Radioiodinated metaiodobenzylguanidine: a review of its biodistribution and pharmacokinetics, drug interactions, cytotoxicity and dosimetry. Europ. J. nucl. Med., 21, 545-559 (1994).
43. WAFELMAN, A.R., HOEFNAGEL, C.A., MAESSEN, H.J.M., MAES, R.A.A. and BEIJNEN, J.H., Renal excretion of iodine-131 labelled meta-iodobenzylguanidine and metabolites after therapeutic doses in patients suffering from different neural crest-derived tumours. Eur. J. nucl. Med., 24, 544-552 (1997).